INVESTMENT RETURNS THROUGH RELENTLESS HEALTH IMPACT

Synthesis Capital invests in technologies and ventures that can change the face of global healthcare

INVESTMENT RETURNS THROUGH RELENTLESS HEALTH IMPACT

Synthesis Capital invests in technologies and ventures that can change the face of global healthcare

INVESTMENT RETURNS THROUGH RELENTLESS HEALTH IMPACT

Synthesis Capital invests in technologies and ventures that can change the face of global healthcare

A thesis of inclusive flourishing

Synthesis Capital invests in early-stage medtech, healthtech and wellbeing-enhancing ventures across the Asia-Pacific. Focusing on deep technology from pre-seed to series A+, we provide ventures with capital pathways and the support they need to take on the world.

Synthesis Capital invests in early-stage medtech, healthtech and wellbeing-enhancing ventures across the Asia-Pacific. Focusing on deep technology from pre-seed to series A+, we provide ventures with capital pathways and the support they need to take on the world.

We fuel and develop ventures across the 5 dimensions of our investment thesis:

We fuel and develop ventures across the 5 dimensions of our investment thesis:

Health & Wellbeing Technologies

Tools to transform physical and mental health including medtech, biotech, deep digital healthtech, including through prevention and early-intervention.

1000

The First 1000

Days of Life

Interventions in paediatrics, prenatal diagnostics, neonatal care, early nutrition and early childhood education, development and parental engagement.

Longevity &

Social Care

Technologies and service design to support inclusive, sustainable social support, mutual care, and preventive and restorative activities.

Augmenting Technologies

Tools to transform human capabilities and allow greater freedom, choice and self-management (education, participation, inclusion).

Climate Change Adaptation

Technologies that meet health system outcomes or operational needs related to climate and zero-carbon adaptation.

OUR UNFAIR ADVANTAGE

OUR UNFAIR ADVANTAGE

Through an exclusive partnership with the MedTech Actuator, Synthesis Capital has a direct line to a diverse pool of investment-ready startups primed for high growth, and access to an entire ecosystem of venture development expertise.

Born as Australia's national medtech venture catalyst, the MedTech Actuator is now one of the Asia-Pacific's leading healthtech commercialisation initiatives, with an outstanding history of success and impact.

By deftly blending finance with active risk management and milestone-based scaling, Synthesis Capital has a distinctive and unprecedented competitive advantage. We're not just investing; we're fostering a new generation of world-leading health enterprises.

The MedTech Actuator's thriving ecosystem is a source of ventures, the means to accelerate their development, and the pathway through which investment gains can be realised.

The MedTech Actuator's thriving ecosystem is a source of ventures, the means to accelerate their development, and the pathway through which investment gains can be realised.

Financial returns through health impact

Synthesis Capital generates investment returns by aligning commercial development with impact optimisation, through an integrated strategy.

Financial returns through health impact

Synthesis Capital generates investment returns by aligning commercial development with impact optimisation, through an integrated strategy.

Financial returns through health impact

Synthesis Capital generates investment returns by aligning commercial development with impact optimisation, through an integrated strategy.

Rapid commercial development

Rapid commercial development

Synthesis Capital propels ventures from the earliest stage onto clear pathways towards scale and growth, using milestone achievements to unlock capital, actively manage risk, and optimise success.

Synthesis Capital propels ventures from the earliest stage onto clear pathways towards scale and growth, using milestone achievements to unlock capital, actively manage risk, and optimise success.

Relentless impact optimisation

Relentless impact optimisation

Our ecosystem helps ventures hone their focus on genuine health challenges and solutions, supporting them to build capabilities that drive better life outcomes across the region and the globe.

Our ecosystem helps ventures hone their focus on genuine health challenges and solutions, supporting them to build capabilities that drive better life outcomes across the region and the globe.

Our Team

Empowering innovation; transforming lives: meet the leaders driving Synthesis Capital

Dr Vishal Kishore Co-Founder

Dr Vishaal Kishore

Managing Partner

Pioneering health innovator with a track record in venture financing and M&A, economic innovation, entrepreneurship, and health system strategy.

Dr Vishal Kishore Co-Founder

Dr Vishaal Kishore

Managing Partner

Pioneering health innovator with a track record in venture financing and M&A, economic innovation, entrepreneurship, and health system strategy.

Dr Buzz Palmer

Investment Partner - Venture Development

Accomplished health entrepreneurship leader with experience in venture capital, product development, and international business scaling.

Dr Buzz Palmer

Investment Partner - Venture Development

Accomplished health entrepreneurship leader with experience in venture capital, product development, and international business scaling.

Tom Bentley

Investment Partner - Ecosystems & Impact

Global social innovation expert with a career in public policy, political advice and public sector investment.

Tom Bentley

Investment Partner - Ecosystems & Impact

Global social innovation expert with a career in public policy, political advice and public sector investment.

Tim Macready

Lead - Investment Governance

Experienced institutional investment professional passionate about capital deployment for transformative financial and social impact.

Tim Macready

Lead - Investment Governance

Experienced institutional investment professional passionate about capital deployment for transformative financial and social impact.

Makenzie Thomas

Portfolio Manager

Ecosystem builder with a multinational career focused on venture development, program management, and health entrepreneurship.

Makenzie Thomas

Portfolio Manager

Ecosystem builder with a multinational career focused on venture development, program management, and health entrepreneurship.

Sophy Tang

Investment Analyst

Finance and tech professional with expertise in wealth management, education tech, and corporate financial advising.

Sophy Tang

Investment Analyst

Finance and tech professional with expertise in wealth management, education tech, and corporate financial advising.

FOR STARTUPS

Supercharge your commercialisation journey

Are you developing a transformative technology or insight with the potential and aspiration for large-scale health impact?

Is your proposition grounded in deep technology, demanding the right approach to IP and regulation?

Is your team driven by passion and purpose, and would you benefit from access to the Asia-Pacific's leading healthtech commercialisation ecosystem?

If yes, then we would love to hear from you!

Synthesis Capital is the catalyst your innovation needs. We are more than an investor; we are your strategic partner, bringing a powerful ecosystem and venture development process dedicated to nurturing your startup's potential, smoothing your journey, and supercharging your route to market.

Synthesis Capital is the catalyst your innovation needs. We are more than an investor; we are your strategic partner, bringing a powerful ecosystem and venture development process dedicated to nurturing your startup's potential, smoothing your journey, and supercharging your route to market.

Let's charge into the future of health - together.

FOR INVESTORS

Investing in tomorrow's health innovations, today

Synthesis Capital is inviting investors to become a part of our mission to revolutionise health and wellbeing enhancement.

  • Based in Melbourne, Australia, we harness the potential of an Asia-Pacific wide ecosystem.

  • Our exclusive partnership with the MedTech Actuator enriches our venture pipeline, offering direct access to companies that have undergone rigorous assessment and commercialisation development.

  • We target returns of over 25% net of fees, carry and expenses.

  • Our investors enjoy optimised tax benefits including a 10% tax offset and tax-free returns, facilitated by our conditional ESCLP registration, with investment flexibility provided through a stapled managed investment trust.

  • At Synthesis Capital, your investment doesn't just yield financial returns - it contributes to health impact and systemic transformation in the healthcare sector.

Ready to shape the future of healthcare?

Your journey starts here

Synthesis Capital Management Pty Ltd (ACN 659 511 547) is a Corporate Authorised Representative (AR 001297029) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (ASL 531197). Synthesis Capital Partnership I LP is conditionally registered as an early stage venture capital limited partnership and further conditions will need to be met before being able to apply to be registered as a complying and fully registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth).

© 2023 Synthesis Capital

Synthesis Capital Management Pty Ltd (ACN 659 511 547) is a Corporate Authorised Representative (AR 001297029) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (ASL 531197). Synthesis Capital Partnership I LP is conditionally registered as an early stage venture capital limited partnership and further conditions will need to be met before being able to apply to be registered as a complying and fully registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth).

© 2023 Synthesis Capital

Synthesis Capital Management Pty Ltd (ACN 659 511 547) is a Corporate Authorised Representative (AR 001297029) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (ASL 531197). Synthesis Capital Partnership I LP is conditionally registered as an early stage venture capital limited partnership and further conditions will need to be met before being able to apply to be registered as a complying and fully registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth).

© 2023 Synthesis Capital